Melanoma
1,450
186
308
671
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
317 trials with published results (22%)
Research Maturity
671 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.7%
228 terminated out of 1450 trials
74.6%
-11.9% vs benchmark
6%
85 trials in Phase 3/4
47%
317 of 671 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 671 completed trials
Clinical Trials (1450)
Family History App in Personalized Medicine
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Clinical Genetics Branch Eligibility Screening Survey
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Integrated Cancer Repository for Cancer Research
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma
DESTINY-PANTUMOUR04
National Cancer Institute "Cancer Moonshot Biobank"
Harvesting Cells for Experimental Cancer Treatments
Evaluation for NCI Surgery Branch Clinical Research Protocols